ALLO-647

BIOLOGICAL8 trials

Sponsors

Allogene Therapeutics Inc., Allogene Therapeutics

Conditions

Advanced/Metastatic Clear Cell Renal Cell CarcinomaLarge B-Cell Lymphoma (LBCL)Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic LymphomaRelapsed/Refractory Follicular LymphomaRelapsed/Refractory Large B Cell LymphomaRelapsed/Refractory Multiple Myeloma

Phase 1

Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma

CompletedNCT03939026

Allogene TherapeuticsRelapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Large B Cell Lymphoma

Start: 2019-05-01End: 2025-01-28Updated: 2026-03-02

Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)

Active, not recruitingNCT04093596

Allogene TherapeuticsRelapsed/Refractory Multiple Myeloma

Start: 2019-09-23End: 2027-09-30Target: 132Updated: 2023-08-14

Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

Active, not recruitingNCT04416984

Allogene TherapeuticsRelapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma

Start: 2020-05-21End: 2029-05-01Target: 160Updated: 2026-03-04

Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Active, not recruitingNCT04696731

Allogene TherapeuticsAdvanced/Metastatic Clear Cell Renal Cell Carcinoma

Start: 2021-02-24End: 2025-12-31Target: 120Updated: 2025-09-25

Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

TerminatedNCT05000450

Allogene TherapeuticsRelapsed/Refractory Multiple Myeloma

Start: 2021-06-06End: 2023-10-11Updated: 2024-06-28

Phase 2

Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy

TerminatedNCT05714345

Allogene TherapeuticsRelapsed/Refractory Large B Cell Lymphoma

Start: 2023-11-01End: 2024-10-28Updated: 2026-03-02

A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects with Relapsed/Refractory Large B Cell Lymphoma (LBCL).

CompletedCTIS2022-501927-25-00

Allogene Therapeutics Inc.Large B-Cell Lymphoma (LBCL)

Start: 2023-09-29End: 2024-01-12Target: 35Updated: 2024-01-15

A Randomized, Open-Label, Phase 2 Study Evaluating Lymphodepletion With Fludarabine, Cyclophosphamide, And ALLO-647, Vs. Fludarabine And Cyclophosphamide Alone, In Subjects With Relapsed/Refractory Large B-Cell Lymphoma (LBCL) Receiving ALLO-501A Allogeneic CAR T Cell Therapy

CompletedCTIS2023-503830-27-00

Allogene Therapeutics Inc.Large B-Cell Lymphoma (LBCL)

Start: 2023-10-17End: 2024-10-28Target: 35Updated: 2024-01-29

Related Papers

ALLO-316 in advanced clear cell renal cell carcinoma (ccRCC): Updated results from the phase 1 TRAVERSE study.

Journal of Clinical Oncology2025-05-283 citations

Discovery of a pan anti-SARS-CoV-2 monoclonal antibody with highly efficient infected cell killing capacity for novel immunotherapeutic approaches

Emerging Microbes & Infections2024-11-253 citations

Clinical Response after Allogeneic CAR T Cell Therapy Is Linked to Expansion of Identical CD8+ Effector-like T Cell Clones

Blood2024-11-05

Immunoinformatics Approach to Design a Chimeric CD70‐Peptide Vaccine against Renal Cell Carcinoma

Journal of Immunology Research2024-01-013 citations

ALLO-647 for Lymphodepletion in the Allogeneic CAR T Setting: Safety Experience with ALLO-501/501A in Patients (Pts) with Relapsed/Refractory (r/r) Large B-Cell and Follicular Lymphomas

Blood2023-11-0213 citations

Cellular Mechanisms Affecting Allogeneic CAR T Cell Expansion and Rejection in Large B-Cell Lymphoma

Blood2023-11-023 citations

P1125: DURABLES RESPONSES ACHIEVED WITH ANTI-CD19 ALLOGENEIC CAR T ALLO-501/501A IN PHASE 1 TRIALS OF AUTOLOGOUS CAR T-NAÏVE PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (R/R LBCL)

HemaSphere2023-08-014 citations

Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501/501A in relapsed/refractory large B-cell lymphoma (r/r LBCL).

Journal of Clinical Oncology2023-06-0116 citations

DURABLES RESPONSES WITH ANTI‐CD19 ALLOGENEIC CAR T ALLO‐501/501A IN PHASE 1 TRIALS OF RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA (<i>R</i>/<i>R</i> LBCL)

Hematological Oncology2023-06-014 citations

Abstract CT011: A phase 1 multicenter study (TRAVERSE) evaluating the safety and efficacy of ALLO-316 following conditioning regimen in pts with advanced or metastatic clear cell renal cell carcinoma (ccRCC)

Cancer Research2023-04-1435 citations

Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

Blood2022-11-1510 citations

Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

Blood2021-11-0547 citations

ALPHA2 Study: ALLO-501A Allogeneic CAR T in LBCL, Updated Results Continue to Show Encouraging Safety and Efficacy with Consolidation Dosing

Blood2021-11-0543 citations

ALPHA Study: ALLO-501 Produced Deep and Durable Responses in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma Comparable to Autologous CAR T

Blood2021-11-0542 citations

First-in-human data of ALLO-501A, an allogeneic chimeric antigen receptor (CAR) T-cell therapy and ALLO-647 in relapsed/refractory large B-cell lymphoma (R/R LBCL): ALPHA2 study.

Journal of Clinical Oncology2021-05-2024 citations

Safety and PK/PD of ALLO-647, an anti-CD52 antibody, with fludarabine (Flu)/cyclophosphamide (Cy) for lymphodepletion in the setting of allogeneic CAR-T cell therapy.

Journal of Clinical Oncology2021-05-2012 citations

Global Perspective on the Development of Genetically Modified Immune Cells for Cancer Therapy.

2021-02-156 citations

Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma

Blood2020-11-0470 citations

First-in-human data of ALLO-501 and ALLO-647 in relapsed/refractory large B-cell or follicular lymphoma (R/R LBCL/FL): ALPHA study.

Journal of Clinical Oncology2020-05-2046 citations